Boehringer Ingelheim has posted growth in local currency (+8.3%) in the first six months of 2009, as compared to the corresponding period previous year. The company reported net sales of E6.38 billion, as compared to E5.52 billion in the first six months of the previous year.
Andreas Barner, chairman of Boehringer Ingelheim, said: We have posted growth in our business areas Human Pharmaceuticals, thanks in particular to the success of our innovative prescription medicines, and in Animal Health, thanks to the growth in the segment of vaccines.
Despite the negative impact in some areas as a result of the financial crisis, local business development in the first half of 2009 shows that Boehringer Ingelheim is maintaining its growth course, virtually unchanged, and continues to outpace the pharmaceutical market, he added.
Boehringer Ingelheim is again expecting sales growth in local currency in the year as a whole, to outpace the world pharma market for the tenth time in succession.